1. The Pharmacokinetic Profile of Tamsulosin Oral Controlled Absorption System (OCAS®) 
Martin C. Michel, Cees Korstanje, Walter Krauwinkel, Mirjam Kuipers 
European Urology Supplements 
Volume 4, Issue 2, Pages (February 2005)
DOI: /j.eursup
Copyright © 2004 Elsevier B.V. Terms and Conditions

2. Fig. 1
Schematic representations of different MR technologies: (A) multi-unit membrane-coated pellets, (B) Oros®, (C) GeoMatrix®.
European Urology Supplements 2005 4, 15-24DOI: ( /j.eursup )
Copyright © 2004 Elsevier B.V. Terms and Conditions

3. Fig. 2
Schematic representation of OCAS® hydration and drug release in small intestine and colon compared with conventional matrix hydration.
European Urology Supplements 2005 4, 15-24DOI: ( /j.eursup )
Copyright © 2004 Elsevier B.V. Terms and Conditions

4. Fig. 3
Tamsulosin OCAS 0.4mg tablet dissolution data (n=6). Dissolution was carried out for the S2, S3 and S4 formulations using the Ph Eur paddle method (200rpm) using water at 37°C as the dissolution medium. Data are expressed as mean±standard deviation.
European Urology Supplements 2005 4, 15-24DOI: ( /j.eursup )
Copyright © 2004 Elsevier B.V. Terms and Conditions

5. Fig. 4
Mean trough plasma concentrations during multiple dosing of one (0.4mg), two (0.8mg) or three (1.2mg) tablets of tamsulosin OCAS S3 0.4mg in the fasted state and one tablet of tamsulosin OCAS S3 0.4mg in the fed state. The curves represent the average values of 24 subjects; the error bars represent the standard deviation.
European Urology Supplements 2005 4, 15-24DOI: ( /j.eursup )
Copyright © 2004 Elsevier B.V. Terms and Conditions

6. Fig. 5
Mean plasma concentration vs. time profiles of multiple dosing of tamsulosin OCAS S3 0.4mg in the fasted and the fed state. The curves represent the average values of 24 subjects. A quantitative analysis of the data is presented in Table 2.
European Urology Supplements 2005 4, 15-24DOI: ( /j.eursup )
Copyright © 2004 Elsevier B.V. Terms and Conditions